Miglitol: Indication, Dosage, Side Effect, Precaution

Generic Medicine Info Full Generic Medicine Info

Dosage/Direction for Use Administration Contraindications Special Precautions Adverse Reactions Pregnancy Category (US FDA) Drug Interactions Action Storage CIMS Class ATC Classification

This information is not country-specific. Please refer to the India prescribing information.

Generic Medicine Info

Administration

Should be taken with food. Take w/ 1st bite of each main meal.

Contraindications

Patient w/ diabetic ketoacidosis, inflammatory bowel disease, colonic ulceration, partial intestinal obstruction or predisposition to this condition, chronic intestinal diseases associated w/ marked disorders of digestion or absorption and co-existing conditions that may deteriorate as a result of increased intestinal gas formation.

Special Precautions

Patient exposed to stress (e.g. fever, trauma, infection, surgery). Renal impairment. Pregnancy and lactation. Patient Counselling Adhere to diet and exercise regimen. Monitoring Parameters Periodic monitoring of blood glucose tests. Measure glycosylated Hb to monitor long term glycaemic control.

Adverse Reactions

Abdominal pain or discomfort, diarrhoea, flatulence, skin rash.

Pregnancy Category (US FDA)

Drug Interactions

Concomitant use w/ insulin increases the risk of hypoglycaemia. Intestinal adsorbents (e.g. charcoal) and carbohydrate-splitting digestive enzyme supplements (e.g. amylase, pancreatin) may reduce glycaemic effects. May significantly reduce the bioavailability of ranitidine and propranolol.

CIMS Class

Antidiabetic Agents

ATC Classification

A10BF02 - miglitol ; Belongs to the class of alpha glucosidase inhibitors. Used in the treatment of diabetes.

Disclaimer: This information is independently developed by CIMS based on miglitol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 CIMS. All rights reserved. Powered by CIMSAsia.com